Project : MMB101
Indication : Immuno-Oncology
| Discovery | Lead Optimization | Preclinical Efficacy | CMC development | IND-enabling | Phase I |
|---|---|---|---|---|---|
MMB101 is a humanized anti-TIGIT monoclonal antibody designed to target a novel epitope
spanning multiple PVR binding sites for optimized functional coverage.
Project : MMB102
Indication : Immuno-Oncology
| Discovery | Lead Optimization | Preclinical Efficacy | CMC development | IND-enabling | Phase I |
|---|---|---|---|---|---|
MMB102 is a GITR agonistic antibody designed to achieve an anti-cancer immune response via deactivation of immuno-suppressive Treg cells and activation of CD8+ effector T cells.
Project : MFA011
Indication : Immuno-Oncology
| Discovery | Lead Optimization | Preclinical Efficacy | CMC development | IND-enabling | Phase I |
|---|---|---|---|---|---|
MFA011 is a fusion antibody with MediMabBio’s proprietary anti-TIGIT antibody and IL15 cytokines.
Project : MFA021
Indication : Immuno-Oncology
| Discovery | Lead Optimization | Preclinical Efficacy | CMC development | IND-enabling | Phase I |
|---|---|---|---|---|---|
Project : MMB301
Indication : Immuno-Oncology
| Discovery | Lead Optimization | Preclinical Efficacy | CMC development | IND-enabling | Phase I |
|---|---|---|---|---|---|
| Product | Indication | Therapeutic Modality | Target | Discovery | Lead Optimization | Preclinical Efficacy | CMC development | IND-enabling | Phase I | Link |
|---|---|---|---|---|---|---|---|---|---|---|
| Oncology | ||||||||||
| MMB101 | Immuno-Oncology | Monoclonal Antibody | anti-TIGIT | Learn more | ||||||
| MMB102 | Immuno-Oncology | Monoclonal Antibody | anti-GITR | Learn more | ||||||
| MFA011 | Immuno-Oncology | Fusion Antibody | anti-TIGIT & IL15R | Learn more | ||||||
| MFA021 | Immuno-Oncology | Fusion Antibody | anti-GITR & IL15R | |||||||
| Inflammatory Disease | ||||||||||
| MMB301 | Autoimmune Disease | Neutralizing Antibody | Undisclosed | |||||||